MockingbirdNews Logo

Mockingbird News

REAL NEWS NEVER FELT FUNNIER

Categories

AI Promises To Speed Cancer Trials While Humans Pretend It’s Magic

KEY POINTS

  • The Tufts Center found AI tools can accelerate cancer drug development by 10 weeks and save $5.6 million in late-stage trials.
  • Medable’s AI agent was applied in phase 2 and 3 oncology trials to reduce patient visits and speed up enrollment.
  • Experts expect AI to become standard in three to five years, improving trial diversity and early drug safety monitoring.

Tufts Center for the Study of Drug Development just dropped a bombshell: AI can shave off 10 weeks and save a whopping $5.6 million during those late-stage cancer drug trials that feel longer than a 3-day Spotify binge. They tested this with Medable’s clinical monitoring AI agent during some vague phase 2/3 oncology trials, resulting in fewer torturous site visits and speedier patient sign-ups. Ken Getz, Tufts' big boss, claims this is the first 'predictive' robot to put financial calculators on steroids. If a drug targets 50 tumors, AI’s savings could hit a Titanic-sinking $565 million. Meanwhile, AI plans to become the self-driving Tesla of clinical trials, helping spot diversity, safety, and effectiveness — because sadly, robots still can't sweet-talk patients into joining.

Share the Story

(1 of 3)

Source: Axios | Published: 8/12/2026 | Author: Adriel Bettelheim

Read the original article →